<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006770</url>
  </required_header>
  <id_info>
    <org_study_id>PLX-CLI-03</org_study_id>
    <nct_id>NCT03006770</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization</brief_title>
  <official_title>Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pluristem Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pluristem Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, placebo-controlled, parallel group, multicenter, Phase III
      study.The study aims to evaluate the Efficacy, Tolerability and Safety of Intramuscular
      Injections of PLX PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with
      Minor Tissue Loss (Rutherford Category 5) who are Unsuitable for Revascularization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to major amputation or death (AFS)</measure>
    <time_frame>Up to 36 months from enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of any of the events (in index leg)-major amputation,revascularization due to worsening of CLI,doubling of total wound area from baseline,anew gangrene. All-cause mortality.</measure>
    <time_frame>Up to 36 months from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to major amputation of the index leg.</measure>
    <time_frame>Up to 36 months from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete wound healing in the index leg</measure>
    <time_frame>12 months from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic pain (NRS).</measure>
    <time_frame>6 months from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to adjudicated major amputation of the index leg or death</measure>
    <time_frame>Up to 36 months from enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Critical Limb Ischemia (CLI)</condition>
  <arm_group>
    <arm_group_label>PLX-PAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PLX-PAD</intervention_name>
    <description>Local intramuscular (IM) injections of PLX-PAD in the index leg.</description>
    <arm_group_label>PLX-PAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Local intramuscular (IM) injections of Placebo in the index leg.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male or female subjects between ages 45-99 years of age.

          2. CLI, with minor tissue loss up to the ankle level (Rutherford Category 5)

          3. Ankle pressure (AP) ≤70 mmHg or TP ≤50 mmHg in the index leg. (If a subject has ABI
             &gt;1.4 and TP is not measureable, inclusion may be based on TcPO2 ≤30 mmHg)

          4. Subject unsuitable for revascularization (by any method) in the index leg.

          5. Ischemic lesions in the index leg stable for at least 2 weeks.

          6. Ischemic ulcers in the index leg without tendon or bone exposure (unless secondary to
             a minor amputation).

          7. Under treatment for cardiovascular risk factors: hypertension, hyperlipidemia,
             diabetes, in accordance with applicable guidelines. Concomitant therapy with a statin
             and an anti-platelet agent for at least 2 weeks prior to randomization.

          8. Women of childbearing potential must have a negative serum pregnancy test at screening
             and must be willing to use at least one highly effective birth control method
             throughout the study.

          9. Signed informed consent form.

        Exclusion Criteria:

          1. Non-atherosclerotic PAD (e.g. Buerger's disease).

          2. CLI with major tissue loss (Rutherford Category 6) in either leg.

          3. Evidence of active infection (e.g., cellulitis, osteomyelitis).

          4. Subject having undergone surgical revascularization or major amputation less than 1
             month prior to screening, or endovascular revascularization or minor amputation less
             than 2 weeks prior to screening.

          5. Planned or potential need for major/minor amputation or any revascularization within 1
             month of study entry upon investigator's judgment.

          6. Aorto-iliac stenosis or common femoral artery stenosis ≥70%, or otherwise suspicion of
             inadequate inflow to the leg.

          7. Life expectancy of less than 6 months.

          8. Stroke or acute myocardial infarction/unstable angina within 3 months prior to
             screening.

          9. Severe congestive heart failure symptoms (New York Heart Association [NYHA] Stage IV).

         10. Uncontrolled severe hypertension.

         11. Diabetes mellitus with HbA1c &gt;10%.

         12. Current or history of proliferative retinopathy.

         13. Known Hepatitis B virus or Hepatitis C virus or acquired immunodeficiency syndrome
             (AIDS) infections.

         14. Subjects with international normalized ratio (INR) &gt;2.5.

         15. Subject on renal replacement therapy or with eGFR &lt;15 mL/min/1.73m2.

         16. Subject is currently enrolled in, or has not yet completed a period of at least 30
             days since ending another investigational device or drug trial(s), unless in long-term
             follow-up phase.

         17. Use of hyperbaric oxygen therapy, prostanoids, spinal cord stimulation, lumbar
             sympathectomy, wound dressing containing cells or growth factors, or topical platelet
             derived growth factor.

         18. Known allergies to any of the following: DMSO, human serum albumin, bovine serum
             albumin.

         19. History of allergic/hypersensitivity reaction to any substance having required
             hospitalization and/or treatment with IV steroids/epinephrine.

         20. Pulmonary disease requiring supplemental oxygen treatment on a daily basis.

         21. Active malignancy or history of malignancy within 5 years prior to study entry.

         22. In the opinion of the investigator, the subject is unsuitable for participating in the
             study.

         23. Inability to understand and provide an informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Miami Leonard M.Miller School of Medicine (UMMSM)-UHealth Pulmonary and Critical Care Medicine-Rosenstiel Building Location</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arash Bornak, MD</last_name>
      <phone>305-284-4093</phone>
      <email>abornak@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Arash Bornak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center (TMC) (Tufts-New England Medical Center)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111-1552</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Iafrati, MD</last_name>
      <phone>617-636-5019</phone>
      <email>miafrati@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Mark Iafrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Heart Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Gammon, MD</last_name>
      <phone>512-206-3600</phone>
      <email>roger.gammon@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Roger Gammon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine Suppl. Leitung der Klin. Abteilung f. Angiologie Medizinische Universtitat Graz - Substitute Head of the Clinical Division of Angiology</name>
      <address>
        <city>Graz</city>
        <zip>A 8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Brodmann, MD</last_name>
      <phone>0043 31638513788</phone>
      <email>marianne.brodmann@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Marianne Brodmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cevni ambulance</name>
      <address>
        <city>Hodonín</city>
        <zip>69501</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matuska Jiri</last_name>
      <phone>00420518341182</phone>
      <email>jiri.matuska@matmed.cz</email>
    </contact>
    <investigator>
      <last_name>Matuska Jiri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angiologicka ambulance</name>
      <address>
        <city>Ostrava Dubina</city>
        <zip>700 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dusan Kucera, MD</last_name>
      <phone>00420 595633202</phone>
      <email>dusan.kucera@vtn.agel.cz</email>
    </contact>
    <investigator>
      <last_name>Dusan Kucera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna Fakultni Nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <zip>12802</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude Lubanda, MD</last_name>
      <phone>00420 774988566</phone>
      <email>jean-claude.lubanda@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>Jean-Claude Lubanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intitute of Clinical and Experimental Medicine</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslav Chlupac, MD</last_name>
      <phone>00420 737385657</phone>
      <email>jaroslav.chlupac@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Jaroslav Chlupac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni a.s., Masarykova nemocnice o.z.</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Sauer, MD</last_name>
      <phone>420 47 711 2504</phone>
      <email>martin.sauer@kzcr.eu</email>
    </contact>
    <contact_backup>
      <last_name>Olga Mucicova, Mgr</last_name>
      <phone>420 477 112 100</phone>
      <email>olga.mucicova@kzcr.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Sauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitats-Herzzentrum Freiburg</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zeller, MD</last_name>
      <phone>0049 76334022431</phone>
      <email>thomas.zeller@herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Zeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch, Klinik fur Angiologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Klein-Weigel, MD</last_name>
      <phone>30940154900</phone>
      <email>peter.klein-weigel@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Peter Klein-Weigel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franziskus-Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berthold Amann, MD</last_name>
      <phone>+493026386117</phone>
      <email>berthold.amann@franziskus-berlin.de</email>
    </contact>
    <investigator>
      <last_name>Berthold Amann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Weiss, MD</last_name>
      <phone>+493514583659</phone>
      <email>Norbert.Weiss@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Norbert Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St.Georg-Angiologische Ambulanz</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrid Nikol, Prof.</last_name>
      <phone>401818852401</phone>
      <email>s.nikol@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Sigrid Nikol, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48155</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Reinecke, MD</last_name>
      <phone>0049 (0) 251 8346068</phone>
      <email>Holger.Reinecke@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Holger Reinecke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz</name>
      <address>
        <city>Szekesfehervar</city>
        <state>Fejer</state>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Menesi</last_name>
      <phone>0036209831112</phone>
      <email>vazoaktiv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rudolf Menesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szent Imre Egyetemi Oktato Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katalin Farkas</last_name>
      <phone>0036 304648600</phone>
      <email>angiologia@szentimrekorhaz.hu</email>
    </contact>
    <investigator>
      <last_name>Katalin Farkas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flor Ferenc County Hospital</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Pecsvarady, MD</last_name>
      <phone>0036 209458919</phone>
      <email>zspecs@upcmail.hu</email>
    </contact>
    <investigator>
      <last_name>Zsolt Pecsvarady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>B-A-Z County and University Teaching Hospital</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lajos Matyas, MD</last_name>
      <phone>0036 646323694</phone>
      <email>multifeet@chello.hu</email>
    </contact>
    <investigator>
      <last_name>Lajos Matyas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Josa Andras Megyei Korhaz</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geza Szabo</last_name>
      <phone>0036 42599700</phone>
      <email>dr.szabo.geza@vazomed.eu</email>
    </contact>
    <investigator>
      <last_name>Geza Szabo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem (PTE) Altalanos Orvostudomanyi Kar (AOK) (University of Pecs Medical School)</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Menyhei</last_name>
      <phone>0036 72 536 000</phone>
      <email>menyhei.gabor@pte.hu</email>
    </contact>
    <investigator>
      <last_name>Gabor Menyhei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 1 im. dr. A. Jurasza</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arkadiusz Jawien</last_name>
      <phone>0048525854040</phone>
      <email>ajawien@ceti.com.pl</email>
    </contact>
    <investigator>
      <last_name>Arkadiusz Jawien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny we Wroclawiu, Osrodek Badawczo-Rozwojowy,Intensywnego Nadzoru Kardlologleznego,</name>
      <address>
        <city>Wrocław</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Witkiewicz, Prof</last_name>
      <phone>0048 601703011</phone>
      <email>witkiewicz@wssk.wroc.pl</email>
    </contact>
    <investigator>
      <last_name>Wojciech Witkiewicz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull And East Yorkshire Women And Children's Hospital-Hull And East Yorkshire Hospitals Nhs Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU32JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Edward Smith, MD</last_name>
      <phone>00441482675784</phone>
      <email>georgeedsmith@gmail.com</email>
    </contact>
    <investigator>
      <last_name>George Edward Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Manu, MD</last_name>
      <phone>0203 299 3704</phone>
      <email>chris.manu@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Chris Manu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>March 11, 2018</last_update_submitted>
  <last_update_submitted_qc>March 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

